Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 5Completed 5Recruiting 2Unknown 1Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

pembrolizumab 3Drug Therapy 3Vincristine 2S 1 (combination) 2Nivolumab 2Gemcitabine 2Cyclophosphamide 2CA-4948 2Bevacizumab 2zimberelimab 1venetoclax 1tivozanib 1titanium silicide 1tisagenlecleucel 1sotigalimab 1propranolol CR 1prednylidene 1pimonidazole 1palbociclib 1mirdametinib 1imisopasem manganese 1gusacitinib 1fludarabine 1deltacortene 1brincidofovir 1axicabtagene ciloleucel 1atezolizumab 1Testosterone Propionate 1Testosterone 1Temozolomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Suspended × IFL protocol × Clear all
NCT05419479 2026-02-24

Switch Maintenance in Pancreatic

Dana-Farber Cancer Institute

Phase 1/2 Suspended
46 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡